Table 3.
Mean levels of AhRL and MIS-ATP, classified according to the development of glucose intolerance or diabetes between 2008 and 2012. Gender differences were compared.
| (2008–2012) | Cases (% total) | AhRL (pM, TCDDeq) | p value | MIS-ATP (% of CSS) | p value | |
|---|---|---|---|---|---|---|
| NGT, remained with NGT (NGT-NGT) | Total | 785 (51.1%) | 1.58 ± 0.88 | Ref. | 95.3 ± 11.5 | Ref. |
| Male | 348 (50.7%) | 1.64 ± 0.90 | Ref. | 95.5 ± 11.2 | Ref. | |
| Female | 437 (51.4%) | 1.53 ± 0.86 | Ref. | 95.1 ± 11.7 | Ref. | |
| NGT, progressed to IGT (NGT-IGT) | Total | 109 (7.1%) | 2.52 ± 1.08 | <0.001 | 89.7 ± 9.9 | <0.001 |
| Male | 38 (5.5%) | 2.45 ± 1.22 | <0.001 | 89.4 ± 11.2 | 0.002 | |
| Female | 71 (8.3%) | 2.52 ± 1.00 | <0.001 | 89.9 ± 9.3 | <0.001 | |
| NGT, progressed to diabetes (NGT-DM) | Total | 25 (1.6%) | 2.69 ± 0.98 | <0.001 | 83.5 ± 10.7 | <0.001 |
| Male | 13 (1.9%) | 2.71 ± 0.90 | <0.001 | 84.8 ± 13.3 | 0.013 | |
| Female | 12 (1.4%) | 2.67 ± 1.10 | <0.001 | 82.7 ± 7.4 | <0.001 | |
| IGT reverted to NGT (IGT-NGT) | Total | 125 (8.1%) | 2.64 ± 1.31 | <0.001 [ref] | 84.3 ± 10.4 | <0.001 [ref] |
| Male | 56 (8.1%) | 2.66 ± 1.32 | <0.001 [ref] | 84.7 ± 11.0 | <0.001 [ref] | |
| Female | 69 (8.1%) | 2.62 ± 1.31 | <0.001 [ref] | 84.9 ± 9.9 | <0.001 [ref] | |
| IGT, remained in IGT (IGT-IGT) | Total | 75 (4.9%) | 3.59 ± 1.27 | <0.001 [<0.001] | 81.9 ± 8.3 | <0.001 [0.070] |
| Male | 21 (3.1%) | 3.51 ± 1.08 | <0.001 | 79.1 ± 7.22 | <0.001 | |
| Female | 54 (6.4%) | 3.62 ± 1.35 | <0.001 | 82.9 ± 8.5 | <0.001 | |
| IGT, progressed to diabetes (IGT-DM) | Total | 44 (2.9%) | 4.04 ± 1.41 | <0.001 [<0.001] | 82.3 ± 9.1 | <0.001 [<0.265] |
| Male | 27 (3.9%) | 4.11 ± 1.30 | <0.001 [<0.002] | 81.2 ± 8.3 | <0.001 [0.111] | |
| Female | 17 (2.0%) | 3.92 ± 1.61 | <0.001 | 84.1 ± 10.3 | <0.001 [0.956] | |
| Remained in diabetes (DM) | Total | 374 (24.3%) | 4.74 ± 1.85 | <0.001 | 80.4 ± 10.6 | <0.001 |
| Male | 184 (26.8%) | 4.75 ± 1.75 | <0.001 | 80.4 ± 10.8 | <0.001 | |
| Female | 190 (22.4%) | 4.73 ± 1.94 | <0.001 | 80.4 ± 10.5 | <0.001 | |
AhRL is expressed as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) equivalents (TCDDeq, pM). MIS-ATP is expressed as a percentage of the 10% charcoal-stripped human serum (CSS)-treated control. Values are expressed as mean ± standard deviation. p values were calculated using Students t-test between subjects with NGT that remained with NGT and the other groups. p values in brackets represent comparisons with the IGT, reverted to NGT group.